p.6 抽出テキスト

AF Atrial fibrillation AM Acute myocarditis AMI Acute myocardial infarction AP Acute pericarditis ARVC Arrhythmogenic right ventricular cardiomyopathy ATG Anti-thymocyte globulin AVB Atrioventricular block B19V Parvovirus B19 CAD Coronary artery disease CD Chagas disease CI Confidence interval CK Creatinine kinase CK-MB Creatinine kinase muscle-brain type CMP Cardiomyopathy CMR Cardiovascular magnetic resonance CMV Cytomegalovirus COVID-19 Coronavirus disease 2019 CP Constrictive pericarditis CPB Cardiopulmonary bypass CRT Cardiac resynchronization therapy CS Cardiac sarcoidosis CT Computed tomography CTLA-4 Cytotoxic T-lymphocyte antigen 4 CTP Cardiac tamponade DCM Dilated cardiomyopathy DNA Deoxyribonucleic acid DSP Desmoplakin EAM Electro-anatomical mapping EBV Epstein–Barr virus ECG Electrocardiogram ECP Effusive–constrictive pericarditis ECV Extracellular volume EF Ejection fraction EGPA Eosinophilic granulomatosis with polyangiitis EM Eosinophilic myocarditis EMB Endomyocardial biopsy ESC European Society of Cardiology ESR Erythrocyte sedimentation rate FDG-PET Fluorodeoxyglucose positron emission tomography FM Fulminant myocarditis FMF Familial Mediterranean fever GCM Giant-cell myocarditis GDMT Guideline-directed medical therapy GLS Global longitudinal strain HAART Highly active antiretroviral therapy HCM Hypertrophic cardiomyopathy HCV Hepatitis C virus HES Hypereosinophilic syndrome HF Heart failure HHV-6 Human herpesvirus 6 HIV Human immunodeficiency virus HR Hazard ratio hs-TnI High-sensitivity troponin I hs-TnT High-sensitivity troponin T HT Heart transplantation IABP Intra-aortic balloon pump ICD Implantable cardioverter-defibrillator ICI Immune checkpoint inhibitor ICU Intensive care unit IFN Interferon IL Interleukin IL-1RA Interleukin-1 receptor antagonist IL-1RL1 IL-1 receptor-like 1 IMPS Inflammatory myopericardial syndrome i.v. Intravenous IVIG Intravenous immunoglobulins JVP Jugular venous pressure LA Left atrial LAG-3 Lymphocyte activation gene 3 LC Lyme carditis LGE Late gadolinium enhancement LLC Lake Louise criteria LM Lymphocytic myocarditis LV Left ventricle LVAD Left ventricular assist device LVEF Left ventricular ejection fraction MACE Major adverse cardiac events MCS Mechanical circulatory support miRNAs MicroRNAs NDLVC Non-dilated left ventricular cardiomyopathy NLRP3 NLR family pyrin domain containing 3 NSAID Non-steroidal anti-inflammatory drug NSVT Non-sustained ventricular tachycardia NT-proBNP N-terminal prohormone of brain natriuretic peptide OR Odds ratio P/LP Pathogenic/likely pathogenic PaM Pregnancy-associated myocarditis PCIS Post-cardiac injury syndrome PCR Polymerase chain reaction PD-1 Programmed cell death protein 1 PD-L1 Programmed death ligand 1 PEff Pericardial effusion PPCM Peripartum cardiomyopathy PPS Post-pericardiotomy syndrome PVS Programmed ventricular stimulation RA Rheumatoid arthritis RAP Right atrial pressure RCM Restrictive cardiomyopathy RCT Randomized controlled trial RNA Ribonucleic acid RP Recurrent pericarditis RV Right ventricle SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SCD Sudden cardiac death SLE Systemic lupus erythematosus SSc Systemic sclerosis TB Tuberculosis TDI Tissue Doppler imaging TF Task Force TNF-α Tumour necrosis factor alpha TRAPS Tumour necrosis factor receptor-associated periodic syndrome TTE Transthoracic echocardiography uIFN-γ Unstimulated interferon gamma VA Ventricular arrhythmias

ESC Guidelines                                                                                                                                                                                          3957

Downloaded from academic.oup.com/eurheartj/article/46/40/3952/8234483 by guest on 07 October 2026